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COMMENTARY

Notes from an epicenter: navigating
behavioral clinical trials on autism spectrum
disorder amid the COVID‑19 pandemic
in the Bronx
Alaina S. Berruti1, Roseann C. Schaaf2, Emily A. Jones3, Elizabeth Ridgway4, Rachel L. Dumont2, Benjamin Leiby5,
Catherine Sancimino1, Misung Yi5 and Sophie Molholm1,6,7*   

Abstract
Background: The COVID-19 pandemic impacted nearly all facets of our daily lives, and clinical research was no
exception. Here, we discuss the impact of the pandemic on our ongoing, three-arm randomized controlled trial (RCT)
Sensory Integration Therapy (SIT) in Autism: Mechanisms and Effectiveness (NCT02536365), which investigates the immediate and sustained utility of SIT to strengthen functional daily-living skills and minimize the presence of maladaptive
sensory behaviors in autistic children.
Main text: In this text, we detail how we navigated the unique challenges that the pandemic brought forth between
the years 2020 and 2021, including the need to rapidly adjust our study protocol, recruitment strategy, and in-person
assessment battery to allow for virtual recruitment and data collection. We further detail how we triaged participants
and allocated limited resources to best preserve our primary outcome measures while prioritizing the safety of our
participants and study team. We specifically note the importance of open and consistent communication with all participating families throughout the pandemic in ensuring all our protocol adjustments were successfully implemented.
Conclusions: Though the COVID-19 pandemic resulted in an unprecedented interruption to in-person clinical
research, clinical trials have always been and will continue to be at risk for unforeseen interruptions, whether from
world events or participants’ personal circumstances. By presenting our steps to preserving this RCT throughout the
pandemic, we offer suggestions for successfully managing unexpected interruptions to research. Ideally, by taking
these into account, future RCTs may be increasingly prepared to minimize the impact of these potential interruptions
to research.
Keywords: COVID-19, Autism spectrum disorder, Behavioral intervention, Sensory integration therapy, Applied
behavior analysis, Randomized controlled trial
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Background
The prolonged COVID-19 pandemic has impacted nearly
all facets of our daily lives since its emergence, and clinical research has been no exception [1]. Here, we describe
how our ongoing, three-arm randomized controlled trial
(RCT) Sensory Integration Therapy in Autism: Mechanisms and Effectiveness navigated the evolving landscape
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of the COVID-19 pandemic between the years 2020 and
2021 (NCT02536365).
Though the phenotype of autism spectrum disorder
(ASD) is heterogeneous to some degree, difficulties in
processing and integrating sensory information have
been reported in approximately 45–95% of autistic individuals [2]. These sensory features impact successful
participation in daily living, learning, and social activities as well as behavior [3, 4], making this an important
area for intervention. Occupational Therapy (OT) using
Ayres Sensory Integration® (SIT) is an evidence-based
intervention that is designed to address these sensory
challenges and improve adaptive behaviors and participation in activities and tasks [5]. As such, our RCT was
designed to improve the understanding of the immediate
and sustained utility of SIT as a means of strengthening
functional daily-living skills and minimizing the presence
of maladaptive sensory behaviors. We aim to compare
SIT mechanisms and effectiveness to that of the applied
behavior analysis (ABA) approach, which has long been
the standard of care for autistic children in need of support in these areas [6].
To answer this question at both the behavioral and
neurophysiological levels, we use an extensive battery of
standardized clinical and OT assessments, parent questionnaires and interviews, and electroencephalography
(EEG) recordings designed to evaluate multiple facets
of our participants’ functional, social, and sensory integration skills. We recruit autistic children between 6

Fig. 1 Flow of participants through RCT
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and 9 and a half years old who (1) demonstrate sensory
dysfunction (as indexed by performance on the Sensory
Integration and Praxis Test (SIPT) [7] and the Sensory
Processing Measure (SPM) [8] at baseline), (2) have a
nonverbal IQ of 70 or above (as indexed by performance
on the Wechsler Abbreviated Scale of Intelligence–Second Edition (WASI-II) [9] at baseline), and (3) are receiving less than 12 h per week of behavioral, speech, or
related therapies outside of those included in their educational programming. Participants are first assessed by
a team of research-reliable psychologists, occupational
therapists, and EEG technicians over the course of three
to four appointments (totaling roughly 15 h of in-person
testing) to establish baseline before being randomized to
one of the three study arms: sensory integration therapy
(SIT), applied behavior analysis (ABA), or no treatment
(NT). Both SIT and ABA participants are provided 30
1-h therapy sessions across 12 weeks, while the NT participants are asked to continue their usual treatment
course outside of the RCT but do not receive any new
therapies. Participants are reassessed immediately (Post
1) following the 12-week intervention period and then
again 12 weeks after that, during what we refer to as Post
2 [10]. See Fig. 1 for a depiction of the standard participation timeline.
At RCT initiation we set out to recruit 180 participants by June 2020, allowing us 60 participants in
each treatment arm. Due to unanticipated recruitment challenges, by March 2020, only 93 participants
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had completed (53) or were enrolled in the RCT (40),
and with a newly enhanced community-based recruitment strategy (discussed later in this commentary),
we expected to reach our initial recruitment goal by
extending the RCT to June 2021 with a one-year nocost funding extension. However, at the onset of the
pandemic, we temporarily paused new enrollments and
shifted our focus to the 40 participants who were active
in various stages of the RCT at Albert Einstein College
of Medicine (AECOM): 12 were completing baseline
evaluations, 11 were actively receiving in-person SIT or
ABA intervention, 10 were in Post 1, and 7 were in Post
2 (Table 1).
As New York City emerged as an epicenter of COVID19 [11], our RCT, along with other nonessential research,
was forced to suspend any in-person research operations
until further notice. With participant safety and wellbeing consistently at the forefront of our decision-making, here, we discuss how we have thus far navigated the
uncertainty of the pandemic and adjusted our protocol
to best preserve the integrity of the RCT. We primarily
focus on the RCT operations at AECOM by first describing our participant sample, then noting our response to
specific challenges brought forth by the pandemic, and
finally, reflecting on what this can teach us about handling unexpected interruptions to research and designing future RCTs. However, at the onset of the pandemic,
we had also been preparing to open a second site for this
RCT at Children’s Specialized Hospital (CSH) in New
Jersey, and we later discuss how we launched recruitment at this site in the wake of COVID-19. Figure 2 offers
a concise presentation of our decision-making timeline
across both sites between March 2020 and June 2021.

Participant demographics
The participants in our RCT from AECOM are representative of the diversity within our local Bronx, New
York community. Approximately 60% of all participants
in our current sample (n=93) reside in the Bronx, and
an additional 10% of participants reside in Harlem

and surrounding neighborhoods in Upper Manhattan.
Additionally, 56% of our sample report identifying as
Hispanic or Latino, which is consistent with 2021 US
Census estimates for the Bronx [12]. Just over 85% of
our sample is male, which is also representative of the
4:1 male-to-female ASD diagnosis ratio traditionally
reported in the literature [13], albeit recent studies
suggest the actual ratio may be closer to 3:1 [14]. We
largely attribute our success in recruiting a representative sample to our community-based outreach strategy,
which is detailed later in this commentary. Nevertheless, our goal in describing our sample’s demographics
here is primarily to provide context for the reader as we
detail our decision-making over the course of the pandemic throughout the remainder of the text.

Establishing a line of communication amid the RCT
suspension (March 2020)
In March 2020, in accordance with institutional policies
at AECOM to pause in-person nonessential research, all
40 participants active in the RCT were directly notified
of the immediate study suspension and told to await further notice regarding eventual study reopening (Fig. 2).
From then on, we maintained a consistent and open
dialogue with these participants via weekly text, phone,
and email messages to provide updates on the state of
the RCT and record any changes to participants’ usual
treatment plan (including medications and external
behavioral interventions). Establishing this line of communication with participants early on was critical in
retaining participants throughout the study suspension
and ensuring that our eventual study modifications and
protocol adaptations were successfully implemented.
Triaging participants to preserve primary outcome
measures (April 2020)
By April 2020, New York City had become an epicenter
of the COVID-19 pandemic, with case counts rising
to roughly 5000 diagnosed cases per day, and rates of

Table 1 Participant breakdown by study stage and randomization status at study shutdown
Sensory integration therapy Applied behavior analysis
(SIT)
(ABA)

No treatment (NT)

Not Yet Randomized

Total

Baseline

-

-

-

12

12

Intervention

5

6

-

-

11

Post 1

1

3

6

-

10

Post 2

4

0

3

-

7

Total

10

9

9

12

40

Table 1 displays the breakdown of the 40 active participants in the RCT in March 2020 when the study was initially suspended. Participants are categorized based on
the treatment arm they had been assigned, or in some cases, it is indicated that participants had not yet been randomized. Participants are further categorized based
on the stage of the study they were completing during the time of the initial study suspension
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Fig. 2 Timeline of decision-making related to COVID-19 impact

hospitalization and death were consistently highest in the
Bronx and among Black and Hispanic or Latino individuals when rates were adjusted for differences in age-distributions among the groups [11]. As it became clear that
the unprecedented interruption of in-person data collection would extend well into the foreseeable future, we
triaged participants in a way that allowed us to focus on
best preserving our RCT’s primary outcome measures in
Post 1. Accordingly, our team made the decision to dismiss the seven participants that had been in Post 2 prior
to study shutdown (Fig. 2). Though these participants had
not fully completed all assessments typically conducted
in this stage, we determined that our resources should be
allocated elsewhere since we already had collected their
Post 1 assessments. Upon dismissal, these participants
were provided with the same packet they would have
received if given the opportunity to complete the study
in full, which included monetary compensation, a written
summary of their assessment results, and a listing of local
SIT and ABA resources.
Early dismissal of Post 2 participants allowed us to then
focus our efforts on collecting datapoints from our Post
1 participants (n=10) as efficiently as possible, which

required modifying our RCT protocol and materials to
allow for remote data collection. At this point, we also
continued our weekly check-ins with our Intervention
(n=11) and Baseline participants (n=12), but we did not
yet ask these participants to complete any remote study
activities.

Designing and implementing Post 1 remote data
collection procedures (May 2020)
As previously noted, the assessment battery performed
at Baseline, Post 1, and Post 2 involved a combination
of neurophysiological, parent-report, and standardized
clinical/OT measures, and each category of assessments
lent itself to varying degrees of remote administration feasibility. For instance, neurophysiological data,
in our case, EEG recordings, could not be conducted
without both the participant and a research technician
being present in our lab’s EEG sound-and-electrically
shielded recording booth, and therefore could not be
modified for remote use. On the other end of the spectrum, we found our parent-report measures more easily
lent themselves to remote administration with minor
adjustments. Specifically, we used videoconferencing
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to remotely conduct and record parent interviews
that were previously conducted in person under prepandemic conditions. We also employed Pearson’s
Q-Global® platform, a web-based system for clinical
assessments and questionnaires, to send parents online
questionnaires. For questionnaires that were not readily available for distribution on the Q-Global platform,
we collected survey data using REDCap (Research Electronic Data Capture), which is a secure, web-based
software platform designed to support data capture for
research studies [15, 16]. Members of our study team
coded individual questionnaire items into our RCT’s
REDCap database and generated unique links for each
parent to complete about their child. Through this, all
questionnaires in our assessment battery could be completed securely online from any computer, smartphone,
or tablet. However, our study team was also available to
complete questionnaires with parents over the phone
by reading all items and answer choices aloud and
recording parents’ responses, though ultimately only
one participant preferred to complete their questionnaires this way.
Despite our success with collecting parent-report
measures online, we determined that some of the standardized clinical/OT assessments were not amenable
to remote administration due to a combination of the
nature of these assessments and a consideration of
the resources accessible to our participant sample. For
instance, the SIPT requires participants to have access to
physical testing materials in order to perform 17 standardized visual, tactile, kinesthetic, and motor tasks. Conducting these assessments remotely would also require
participants to have access to reliable high-speed internet, as well as ample space and appropriate testing materials to conduct assessments within their home, which
was not necessarily guaranteed for all participants in
our sample and not something we could provide to all
our participants. Moreover, regardless of the extent to
which remote assessment was feasible, we also considered that these assessments may be influenced by the different modes of administration, which raised concerns
about collecting Post 1 assessments remotely when all
pre-pandemic Baseline assessments had been collected
in-person. As such, we opted to not pursue any remote
clinical or OT assessments with our participants. Instead,
we waited until we could safely resume in-person study
visits to conduct any of these standardized assessments
with study participants.
Of the 10 participants in Post 1 at the time of study
shutdown (Table 1), a total of seven parents needed to
complete remote interviews with our study team, and
all did so successfully. Moreover, all 10 participants each
received five online questionnaires to complete. Of the
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50 total questionnaires distributed, 88% were completed
successfully, with the incomplete 12% resulting from two
participants who opted to discontinue their participation
because of the COVID-19 pandemic.

Re‑triaging participants amid an unexpectedly
prolonged RCT suspension (July 2020)
Following the success of administering questionnaires
and interviews remotely for the Post 1 group and facing continued restrictions on in-person data collection,
we then turned our attention to the 11 participants who
were amid intervention at the point of the March 2020
RCT suspension (Table 1). Within this group, we divided
participants into two categories: (1) participants less than
halfway through intervention (n=6) and (2) participants
more than halfway through intervention (n=5). Notably, participants in the former group had completed an
average of only 2.3 therapy sessions prior to the study
suspension, while those in the latter group had completed an average of 17.4 sessions at this point. We asked
all participants who were more than halfway through
their intervention to begin remotely completing their
Post 1 questionnaires and interviews early (i.e., prior to
completing all planned 30 therapy sessions of the intervention stage) (Fig. 2). We decided to skip to the Post 1
testing, as opposed to conducting remote therapy sessions to make up the remainder first, due to the inherent
inconsistencies between in-person and remote therapy
delivery, particularly for SIT, which participants previously conducted in a sensory gym. And, considering that
these participants had already completed most of their
therapy sessions in-person four months prior, the study
team chose to prioritize collecting Post 1 measures as
close to the pre-pandemic intervention period as possible. Understanding that participants assigned to an active
treatment condition expected to receive 30 therapy sessions, these participants were offered make-up therapy
sessions after they completed their participation in the
Post 1. Our newly dubbed “Early Post 1” group (i.e., those
more than halfway through intervention (n=5)) was
agreeable to the changes to their participation timelines,
and all participants completed their remote questionnaires and interviews successfully except for one who
elected to discontinue their participation due to personal
circumstances.
As “Early Post 1” participants completed remote
assessments, we also developed plans for the remaining 18 participants enrolled in the RCT (Baseline participants (n=12) and Intervention participants less than
halfway through therapy (n=6)). We determined that too
much time would have passed between Baseline and Post
1 for the comparison to be valid and decided we would
need to establish a new post-pandemic baseline for these
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participants before they could progress further in the
RCT. Additionally, we decided that the six participants
who had already been randomized into a treatment arm
would not be re-randomized (i.e., they would stay in their
assigned treatment arm), and once a new baseline was
established, they would restart their 30 therapy sessions
from zero, regardless of how many sessions they had
completed pre-pandemic. However, we would not restart
their study participation until we were safely able to conduct in-person assessments and confident that their participation would not be significantly interrupted by the
pandemic.

Cautiously resuming in‑person study activities
(November 2020)
In November 2020, we were able to resume in-person
study activities in a highly limited capacity, constrained
by continued physical distancing and limited occupancy
guidelines (Fig. 2). Here, we again prioritized providing
our remaining Post 1 (n=8; due to two participants dropping out) and early Post 1 (n=4; due to one participant
dropping out) participants, who had already completed
all Post 1 interviews and questionnaires remotely, with
the opportunity to complete the remaining in-person
Post 1 assessments. By February 2021, these participants
had completed all required in-person assessments except
for one participant who elected to not return for in-person study activities (Fig. 2). These participants were not
asked to return for Post 2 testing, given their already significant Post 1 timeline interruption and the continued
uncertainty of whether the pandemic would again disrupt future in-person data collection. As with our Post
2 participants that were dismissed in April 2020, these
participants were given the same dismissal package they
would have been given if they had completed the study
in full. Additionally, the “Early Post 1” participants were
offered the opportunity to make up any of their remaining therapy sessions with our team, and all four participants chose to do so (Fig. 2).
Allocating RCT resources across two recruitment
sites (May 2021)
In the following months, our team began preparations to
restart the remaining 18 participants, but in May 2021,
we made the difficult decision to instead dismiss these
participants from the RCT. This decision was motivated
by several reasons, but chief among them was the limited
resources available to us as we moved into our second
no-cost funding extension year for this study. Moreover,
in the months just before the COVID-19 pandemic, our
team had prepared to launch a second recruitment site at
CSH in order to expand our enrollment capacity. Though
restrictions on non-essential research operations at CSH
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had previously stalled recruitment at this site, our ability to open enrollment at CSH persuaded us to focus our
efforts on study operations at one site instead of dividing
our efforts across two. As such, participants at AECOM
were immediately notified of our decision to not restart
the study at this site, thanked for their patience throughout the pandemic, and provided with standard dismissal
packets regardless of how much of the study they had
completed. Again, in addition to monetary compensation, these dismissal packets included a summary of any
previous testing participants completed as part of the
study and information about local providers which they
could explore if they were interested in continuing ABA
or SIT services. Additionally, we decided to revise our
original target recruitment goal from 60 participants per
treatment arm to 45 participants per treatment arm in
light of the COVID-19 pandemic and its challenges. We
conducted an interim futility analysis with the data from
all subjects who had completed post-treatment evaluation (15–20 participants per treatment arm). We calculated that this revised sample target would still have
sufficient power to detect differences between the groups
on at least one of our primary outcome measures and
would be a more realistic goal moving forward in the
wake of the COVID-19 pandemic.

Developing a virtual recruitment strategy (June
2021)
Throughout the pandemic, before deciding against
restarting enrollment at AECOM, we had continued
our efforts to promote the study in preparation for an
eventual restart. However, our pre-pandemic recruitment strategy had prioritized hosting and tabling at large
events within the community, including autism resource
fairs, parent workshops, and advocacy walks. Part of
what had made this strategy successful in recruiting a
representative sample for this RCT was that these large
community events gave us an opportunity to interact
face-to-face with community members and explain our
research goals and procedures to individuals who perhaps never participated in research before or were skeptical of doing so. Members of the study team would bring
study flyers, information about SIT and ABA therapies,
and model EEG caps to showcase what it would be like
to participate in our RCT and answer questions about
the study. However, because of the prolonged COVID19 pandemic and continued physical distancing guidelines, these large in-person events became infeasible. As
such, we needed to redesign our recruitment strategy to
adapt to the restrictions COVID-19 placed on in-person
events.
In some instances, when previously in-person events
turned to a virtual format, we worked with event
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organizers to host brief presentations about our research
during the events so that participants would have the
opportunity to still meet and hear from the study team
directly. However, virtual attendance was unfortunately
only a small fraction of the typical turnout for these inperson events, leading us to invest in additional recruitment avenues to complement these efforts.
One solution we developed was to forge more connections with local healthcare providers who often work
with autistic children within the age range for this RCT.
Though this recruitment method does not allow for the
participant to interface with the study team directly the
way that in-person events do, it does allow participants to
learn about the study and have their questions answered
from a professional they already have a relationship with.
To further streamline this effort, we developed an online
portal in REDCap and obtained IRB permissions to allow
providers to share patient contact information (only if
the patient expressed interest in the study and provided
consent to this sharing) with the RCT so that the study
team could follow up with the patient instead of, for
example, the patient needing to remember to call the
study team when they got home from an appointment
with their healthcare provider. This we felt would be crucial in minimizing the steps participants needed to take
to enroll in the RCT and, therefore, minimize the loss
of participants during the recruitment process. Furthermore, we pursued a robust online recruitment strategy,
where we used our connections with community advocacy organizations to spread the word about this RCT to
the families they work with through their online newsletters and webpages. We also employed our lab’s own social
media channels to promote the study by posting our IRBapproved flyers and infographics.
Though we ultimately decided to not continue enrollment at AECOM, this shift in recruitment strategy better prepared us to launch recruitment efforts at CSH, as
COVID-19 restrictions on large in-person events persisted in June 2021. For recruitment at CSH, we have
drawn from our efforts at AECOM and worked to establish connections with local healthcare providers within
CSH’s network to connect their patients with this RCT.
We also expanded our online recruitment efforts by promoting our study on social media and utilized CSH’s
patient database to share information about our study.
Though restrictions on in-person research activities prevented us from enrolling participants until November
2021, laying this groundwork during the initial site setup
meant that we were able to generate 35+ inquiries (community members expressing interest in enrollment) in
the initial weeks of our site launch. However, with the
surge of the COVID-19 Omnicron variant in December 2021, we opted to enroll participants more gradually

Page 7 of 9

than initially planned in order to ensure that we could
accommodate all participants’ time-sensitive, in-person
evaluations while allowing for recommended physical
distancing. As of July 2022, we have enrolled 4 participants in the RCT and we recently resumed our attendance at in-person recruitment events and continue to
look for ways to connect with the local community while
abiding by COVID-19 safety protocols.

Confirming ASD diagnosis under continued mask
mandates (June 2021)
Under pre-pandemic conditions, our RCT employed the
Autism Diagnostic Observational Schedule, Second Edition (ADOS-2), which is a gold-standard, highly structured, ASD diagnostic tool that can quantitatively assess
the severity of ASD behaviors in multiple domains [17].
In our case, the ADOS-2 was utilized to confirm ASD
diagnosis at baseline, to stratify our groups based on ASD
severity scores, and finally, as one of our secondary outcome measures indexing change in the severity of typical autistic behaviors because of intervention. Though
the ADOS-2 had not been extensively validated as an
outcome measure at the time of RCT conception [18],
by collecting these data, we intended to assess ADOS-2
severity scores’ sensitivity to change, and notably, emerging research suggests these scores can serve as sensitive
outcome measures [19]. Nevertheless, as a result of the
prolonged COVID-19 pandemic, continued masking
guidelines have prevented researchers from conducting ADOS-2 assessments, as wearing a mask during the
ADOS-2 compromises its validity [20] since the examiner’s interpretation of the examinee’s organic facial
expressions is integral to obtaining a severity score. We
therefore sought an alternative assessment to utilize in
the continuation of this RCT.
The Childhood Autism Rating Scale, Second Edition
(CARS-2) [21, 22] quickly emerged as the most promising alternative to the ADOS-2 in the context of this RCT
for several reasons. Most notably, administering the
CARS-2 does not require interaction between a researchreliable psychologist and participant, as is the case for the
ADOS-2, and does not require a set of specialized props.
Instead, the CARS-2 is designed such that a psychologist observes participant behavior, and observation can
be done either remotely or through a one-way observation mirror; additionally, the CARS-2-obs model allows
the examiner to observe caregiver-participant interaction
to identify behaviors consistent with ASD [23]. In either
case, the CARS-2 allows for reliable ASD diagnostic
assessment without the need for close interaction with a
participant, which made it a promising solution to continuing assessment in the wake of physical-distancing
guidelines. Furthermore, the CARS-2 offers cutoff scores,
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Table 2 Summary of recommendations for future RCT design and managing unexpected interruptions to research
• When designing future RCTs, we suggest choosing assessments with virtual-adaptability whenever possible, making specific note not only of the
validity of these assessments when conducted remotely, but also their practical feasibility given ones’s participant population.
• When faced with unexpected interruptions to research, we further stress the importance of triaging paticipants to best preserve an RCTs primary
outcome measures, while still honoring commitments to participants and keeping an open dialogue with them such that their voices can continue
to guide decision-making.

standard scores, and percentiles to determine ASD symptom severity, which allows us to still stratify our randomization based on ASD severity.

Conclusions
In reflecting on our experience suspending and then
gradually restarting our RCT, the importance of keeping
participants at the forefront of decision-making cannot
be overstated. Of course, we mean this with respect to
assuring our study modifications prioritized their safety
from COVID-19, but also in the sense of considering the
feasibility for participants to adhere to the modifications
we wished to make, and in consideration of maintaining
the scientific rigor of the trial. For instance, when determining how to proceed with remote assessment, converting the entirety of our assessment protocol to a remote
format would have allowed us to better preserve the
intended timeline of this RCT. However, we had to consider whether our participants had sufficient access to
stable internet, appropriate testing materials, and ample
testing space in their homes, and this ultimately led us to
virtualize our assessment battery only partially until inperson visits were safe to conduct. Therefore, for future
RCTs, we would recommend considering the feasibility and validity of remote assessments when designing a
testing protocol, as choosing assessments that are suitable for either in-person or remote administration would
allow for greater flexibility when scheduling appointments and therefore better adherence to planned participation timelines. Greater remote participation options
may also be well received by participants, who may have
grown accustomed to accessing these opportunities virtually and/or prefer to continue to limit in-person activities due to continued health concerns or for the sake of
convenience.
Furthermore, maintaining a consistent dialogue with
all active participants and triaging participants to best
preserve our primary outcome measures was essential
to navigating the dynamic unfolding of the COVID-19
pandemic. Participants were contacted weekly by the
study team to check in with families and provide updates
on the status of the RCT. In doing so, we were able to
accurately record any changes to participants’ treatment plans outside of the RCT, ensure timely completion of remote assessments, and eventually, coordinate

in-person assessments safely and efficiently. And, having
an open line of communication with participants allowed
us to keep careful note of variables that were beyond our
control, including whether participants were attending
school virtually, in-person, or a mix of the two. As such,
we believe that effective triaging and communication are
key to preserving the most critical elements of RCTs in
the face of unexpected interruptions to research.
The pandemic sparked unprecedented interruption to
daily life on a worldwide scale that one hopes is a oncein-a-century event. Nevertheless, this experience makes
clear that assuming the possibility of such disruptions to
life, and therefore clinical research, again, would be wise.
Indeed, clinical trials have always been and will continue
to be at risk for major or minor interruptions, whether it
be from extreme weather events, participants’ schedules,
or other unforeseen circumstances [24]. This is particularly the case when considering RCTs such as ours, which
originally relied solely on in-person appointments over
an extended timeframe (6 to 9 months). In documenting
how our RCT navigated the COVID-19 pandemic, our
goal is to provide a recommendations (Table 2) within
which to plan for these potential events while conceptualizing future RCTs and managing unexpected interruptions to research.
Abbreviations
ABA: Applied behavior analysis; ADOS-2: Autism Diagnostic Observation
Schedule, Second Edition; AECOM: Albert Einstein College of Medicine; ASD:
Autism spectrum disorder; CARS-2: Childhood Autism Rating Scale, Second
Edition; CSH: Children’s Specialized Hospital; EEG: Electroencephalogram; IRB:
Institutional Review Board; NT: No treatment; OT: Occupational Therapy; RCT:
Randomized control trial; REDCap: Research Electronic Data Capture; SIPT: Sensory Integration and Praxis Test; SIT: Occupational Therapy using Ayres Sensory
Integration® Therapy; SPM: Sensory Processing Measure; WASI-II: Wechsler
Abbreviated Scale of Intelligence–Second Edition.
Acknowledgments
We extend our sincerest thanks to all our families who have graciously dedicated their time to participate in this project and remained engaged in this
research despite the uncertainty of the COVID-19 pandemic. This work would
also not be possible without the support of our study team and independent
evaluators throughout the pandemic, including John Eboli, Regina Freeman,
Catherine Halpern, Joanne Hunt, Anna Keenaghan, Leon Kirschner, and Taylor
Sivori.
Authors’ contributions
ASB wrote the first draft of the manuscript with guidance from SM. RCS,
EAJ, ER, RLD, BL, CS, and MY provided editorial input on subsequent drafts.
All authors were instrumental in the decision-making and successful

Berruti et al. Trials

(2022) 23:691

implementation of new policies and procedures that allowed us to preserve
the trial throughout the COVID-19 pandemic. The author(s) read and
approved the final manuscript.
Funding
Support for this clinical trial is provided by the Eunice Kennedy Shriver
National Institute of Child Health & Human Development (NICHD)
(1R01HD082814-01A1). Additional support came through an NICHD center
grant (P50 HD105352) for the Rose F. Kennedy Intellectual and Developmental
Disabilities Research Center (RFK-IDDRC).
Availability of data and materials
Data sharing is not applicable to this article as no datasets were analyzed during the current study and data collection is ongoing.

Declarations
Ethics approval and consent to participate
All procedures were approved by the Institutional Review Board of the Albert
Einstein College of Medicine and a parent or legal guardian provided consent
for their child to participate before enrollment. All aspects of the research
conformed to the tenets of the Declaration of Helsinki.
Competing interests
The authors declare that they have no competing interests.
Author details
1
The Cognitive Neurophysiology Laboratory, Department of Pediatrics, Albert
Einstein College of Medicine, Bronx, NY, USA. 2 Department of Occupational
Therapy, Thomas Jefferson University School of Rehabilitation Sciences, Philadelphia, PA, USA. 3 Department of Psychology, Queens College and the Graduate Center, City University of New York, Queens, NY, USA. 4 The Children’s
Evaluation and Rehabilitation Center, Department of Pediatrics, Albert Einstein
College of Medicine, Bronx, NY, USA. 5 Division of Biostatistics, Thomas Jefferson University, Philadelphia, PA, USA. 6 Department of Neuroscience, Albert
Einstein College of Medicine, Bronx, NY, USA. 7 Department of Psychiatry
and Behavioral Sciences, Albert Einstein College of Medicine, Bronx, NY, USA.
Received: 22 June 2022 Accepted: 4 August 2022

References
1. Sathian B, Asim M, Banerjee I, Pizarro AB, Roy B, van Teijlingen ER, et al.
Impact of COVID-19 on clinical trials and clinical research: a systematic
review. Nepal J Epidemiol. 2020;10(3):878–87.
2. Ben-Sasson A, Hen L, Fluss R, Cermak SA, Engel-Yeger B, Gal E. A metaanalysis of sensory modulation symptoms in individuals with autism
spectrum disorders. J Autism Dev Disord. 2008;39(1):1–11.
3. Baum SH, Stevenson RA, Wallace MT. Behavioral, perceptual, and neural
alterations in sensory and multisensory function in autism spectrum
disorder. Prog Neurobiol. 2015;134:140–60.
4. Robertson AE, Simmons DR. The relationship between sensory sensitivity and autistic traits in the general population. J Autism Dev Disord.
2012;43(4):775–84.
5. Schaaf RC, Mailloux Z. A clinician’s guide for implementing Ayres Sensory
Integration: Promoting participation in children with autism. Bethesda:
American Occupational Therapy Association Press; 2015.
6. Makrygianni MK, Gena A, Katoudi S, Galanis P. The effectiveness of applied
behavior analytic interventions for children with autism spectrum disorder: a meta-analytic study. Res Autism Spectr Disord. 2018;51:18–31.
7. Ayres AJ. Sensory integration and praxis tests (SIPT). Los Angeles: Western
Psychological Services (WPS); 1996.
8. Parham LD, Ecker C, Miller-Kuhaneck H, Henry DA, Glennon TJ. Sensory
processing measure (SPM). Los Angeles: Western Psychological Services
(WPS); 2007.
9. Wechsler D. Wechsler abbreviated scale of intelligence–second edition
(WASI-II). San Antonio: Pearson; 2011.

Page 9 of 9

10. Sensory integration therapy in autism: mechanisms and effectiveness.
Clinicaltrials.gov. https://clinicaltrials.gov/ct2/show/NCT02536365.
Accessed 29 July 2022.
11. Thompson CN, Baumgartner J, Pichardo C, Toro B, Li L, Arciuolo R, et al.
COVID-19 outbreak — New York City, February 29–June 1, 2020. MMWR
Morb Mortal Wkly Rep. 2020;69:1725–9.
12. U.S. Census Bureau QuickFacts: Bronx County: United States Census
Bureau. https://www.census.gov/quickfacts/fact/table/bronxcountynewy
ork/PST045221. Accessed 17 Mar 2022.
13. Fombonne E. Epidemiology of pervasive developmental disorders. Pediatr Res. 2009;65(6):591–8.
14. Loomes R, Hull L, Mandy WPL. What is the male-to-female ratio in autism
spectrum disorder? A systematic review and meta-analysis. J Am Acad
Child Adolesc Psychiatry. 2017;56(6):466–74.
15. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research
electronic data capture (REDCap)—a metadata-driven methodology and
workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–81.
16. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L, et al. The
REDCap consortium: building an international community of software
platform partners. J Biomed Inform. 2019;95:103208.
17. Lord C, Rutter M, DiLavore PC, Risi S, Gotham K, Bishop SL. Autism diagnostic observation schedule, second edition (ADOS-2) modules 1-4. Los
Angeles: Western Psychological Services (WPS); 2012.
18. Anagnostou E, Jones N, Huerta M, Halladay AK, Wang P, Scahill L, et al.
Measuring social communication behaviors as a treatment endpoint in
individuals with autism spectrum disorder. Autism. 2015;19(5):622–36.
19. Carruthers S, Charman T, El Hawi N, Kim YA, Randle R, Lord C, et al.
Utility of the Autism Diagnostic Observation Schedule and the Brief
Observation of social and communication change for measuring
outcomes for a parent-mediated early autism intervention. Autism Res.
2021;14(2):411–25.
20. Assessment telepractice & telehealth resources. Wpspublish.com. https://
pages.wpspublish.com/telepractice-101. Accessed 28 Mar 2022.
21. Schopler E, Reichler RJ, DeVellis RF, Daly K. Toward objective classification
of childhood autism: Childhood Autism Rating Scale (CARS). J Autism Dev
Disord. 1980;10(1):91–103.
22. Schopler E, Van Bourgondien M, Wellman J, Love S. Childhood autism
rating scale—second edition (CARS-2): manual. Los Angeles: Western
Psychological Services (WPS); 2010.
23. Sanchez MJ, Constantino JN. Expediting clinician assessment in
the diagnosis of autism spectrum disorder. Dev Med Child Neurol.
2020;62(7):806–12.
24. Greenberg RG, Gamel B, Bloom D, Bradley J, Jafri HS, Hinton D, et al.
Parents’ perceived obstacles to pediatric clinical trial participation: findings from the clinical trials transformation initiative. Contemp Clin Trials
Commun. 2018;9:33–9.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

